Eli Lilly (NYSE:LLY) stock moved higher Wednesday, gaining roughly 4% after the U.S. Food and Drug Administration approved Foundayo (orforglipron), the company’s once-daily oral GLP-1 therapy for weight reduction. The medication can be taken without food or water restrictions, and the decision represents Lilly’s second obesity treatment to win FDA clearance.
Foundayo will initially be distributed through LillyDirect, with free home delivery. Under that program, people with commercial coverage will see starting costs of $25 per month, while self-pay customers will face a $149 monthly price. The company also offers a Foundayo savings card that may reduce out-of-pocket costs for eligible commercially insured patients to as little as $25 per month. For eligible Medicare Part D beneficiaries, access may be available at $50 per month beginning as soon as July 1, 2026.
Prescriptions for Foundayo will be accepted immediately, and shipping is scheduled to begin on April 6. Following that launch, the drug will be rolled out through U.S. retail pharmacies and through telehealth providers.
Clinical data from the ATTAIN-1 trial showed meaningful weight reductions among adults taking Foundayo. Participants on the highest dose averaged a loss of 27.3 pounds, equal to 12.4% of body weight, compared with a 2.2-pound (0.9%) average loss for those on placebo. Looking across participants who took Foundayo regardless of trial completion, the average weight loss was 25 pounds, or 11.1%, versus 5.3 pounds (2.1%) for placebo.
Beyond weight reduction, the broader ATTAIN program reported that Foundayo produced declines in several markers associated with cardiovascular risk. Across doses, trial results included reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure.
The approval authorizes use in adults with obesity as well as in adults who are overweight and have weight-related medical conditions. The medication is intended to be used in combination with a reduced-calorie diet and increased physical activity.
Lilly has submitted orforglipron applications for weight management and/or type 2 diabetes in more than 40 countries and intends to launch in each market shortly after regulatory approval.
Market reaction and availability
The stock move followed the FDA announcement and precedes the start of shipping on April 6. Commercial and self-pay pricing under LillyDirect, along with savings-card and Medicare Part D pathways, outline multiple routes for patient access in the U.S.